Cat. No. 5296
Alternative Name: [Pen5,DTrp7,Orn8]hU-II(4-11)
Biological ActivitySelective and competitive urotensin-II (UT) receptor antagonist (pKB = 8.3). Blocks hU-II induced contractions in thoracic aorta ex vivo. Exhibits no effect on noradrenaline or endothelin 1-induced contraction or on acetylcholine-induced relaxation. Behaves as a partial agonist in a calcium mobilization assay (in CHO cells expressing hUT receptors).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Carotenuto et al (2014) Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor. J.Med.Chem. 57 5965. PMID: 24992374.
Patacchini et al (2003) Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br.J.Pharmacol. 140 1155. PMID: 14645137.
If you know of a relevant reference for Urantide please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Urantide from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Urantide, supplier, Selective, competitive, urotensin, II, antagonists, Tocris Bioscience, Urotensin-II Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Negative control for ELA-32 (Cat.No.6291).ELA-32 (human)
Potent, high affinity apelin receptor agonist; stimulates angiogenesisParathyroid hormone (1-34) (bovine)
Parathyroid hormone (PTH) receptor agonist.Parathyroid hormone (1-34) (rat)
Parathyroid hormone (PTH) receptor agonistPeptide YY (3-36) human
NPY Y2 receptor agonistELA-14 negative control
Negative control for ELA-14 (Cat.No.6293).ELA-14 (human)
Potent apelin (APJ) receptor agonistRetrobradykinin
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailable
August 20 - 24, 2017
Paris , France